CN107540569B - Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof - Google Patents
Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof Download PDFInfo
- Publication number
- CN107540569B CN107540569B CN201710818523.0A CN201710818523A CN107540569B CN 107540569 B CN107540569 B CN 107540569B CN 201710818523 A CN201710818523 A CN 201710818523A CN 107540569 B CN107540569 B CN 107540569B
- Authority
- CN
- China
- Prior art keywords
- laminine
- bromo
- hydrochloride
- solution
- oxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a laminine ester group bromo-oxamide derivative with anticancer activity and a composition thereof, and a preparation method comprises the following steps: refluxing laminine hydrochloride in thionyl chloride, adding methanol for refluxing, evaporating redundant solvent, adjusting to be neutral, separating out white precipitate, filtering, washing with glacial ethanol and ethyl ether, drying in vacuum to obtain a white solid product, dissolving N- (5-bromo-2-hydroxyanilino) oxalyl ethyl ester in an absolute ethanol solution, slowly dripping into absolute THF (tetrahydrofuran) in which the prepared 6-N, N, N-trimethyl-2-carbamoylmethylamine hydrochloride is dissolved, heating for reaction, adjusting the solution to be neutral by using a dilute hydrochloric acid or dilute hydrobromic acid solution, separating out white precipitate, filtering, taking precipitate, recrystallizing by using ethanol, and drying in vacuum to obtain the target product. The laminine ester bromo-oxamide derivative and the composition thereof prepared by the invention can enhance the in-vitro cytotoxic activity of laminine on tumor cell strains by introducing a bromo-ring structure.
Description
Technical Field
The invention belongs to the technical field of drug synthesis, and particularly relates to an laminine ester group bromo-oxamide derivative with anticancer activity and a composition thereof.
Background
Laminine is a non-protein amino acid extracted from brown algae, isoxophyta and other plants, is a marine natural product with high activity and no toxic and side effects, and can effectively inhibit the growth of cancer cells. The bioactive substances derived from oceans have unique structure, so that the bioactive substances have higher toxicity while obtaining higher activity. For example, the research personnel screening and researching the antitumor activity of Shandong coastal seaweed discovers that the extract of green alga ulva pertusa has higher cytotoxic activity to human body cavity tumor KB cells and HT-29 cells, but also has higher toxicity to human body normal cells NIK-3T 3. Laminine is a few marine natural products with high activity and low toxicity. The research finds that the acute toxicity of the laminine to the intravenous injection of the mice is 394mg/kg, and the laminine is non-protein amino acid of practical non-toxic grade.
Since the biological activity exhibited by a drug depends mainly on the chemical structure of the drug, the change in chemical structure causes a change in the physicochemical properties of the drug, thereby affecting the absorption and distribution of the drug, the binding to enzymes and receptors, and the metabolism of the drug. The invention synthesizes the laminine derivative by methods of biological isosteric replacement, introduction of cyclic groups to change the three-dimensional structure and the like, researches show that the introduction of brominated cyclic structures can enhance the in vitro cytotoxic activity of laminine on tumor cell strains, and the invention also aims to provide the laminine derivative.
Disclosure of Invention
The invention aims to make up the defects in the current research and application situations of the anti-cancer drugs, and provides an laminine ester-based bromo-oxamide derivative with anti-cancer activity and a composition thereof by introducing a bromo-ring structure through laminine which is a natural marine non-protein amino acid.
In order to achieve the purpose, the invention adopts the following technical scheme:
an laminine-based bromo-oxamide derivative with anticancer activity and a composition thereof are disclosed, wherein the laminine-based bromo-oxamide derivative has a structural formula as follows:
further, the anion A in the structural formula of the laminine ester group bromo-oxamide derivative—Is Cl—Or Br—Or NO3 —。
Further, the preparation method of the laminine ester group bromo-oxamide derivative with anticancer activity and the composition thereof comprises the following steps:
(1) synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: refluxing laminine hydrochloride in thionyl chloride for 2-3h, then adding methanol, continuously refluxing for 3-8h, evaporating redundant solvent, adjusting the pH value to be neutral by using dilute hydrochloric acid until white precipitate is separated out, filtering, washing with glacial ethanol and diethyl ether respectively for multiple times, and drying in vacuum to obtain a white solid product, wherein the yield of the white solid product is 43.7-68.1%;
(2) synthesis of laminine ester group bromo-oxamide derivative: dissolving N- (5-bromo-2-hydroxyanilino) oxalylethyl ester in an absolute ethanol solution, slowly dropwise adding the solution into absolute THF (tetrahydrofuran) in which 6-N, N, N-trimethyl-2-carbamoylmethylamine hydrochloride prepared in the step (1) is dissolved under an ice bath condition, maintaining the reaction for 60min, then heating to 35-85 ℃, heating for reaction for 4-10h, adjusting the pH value of the solution to be neutral by using dilute hydrochloric acid or dilute hydrobromic acid solution until white precipitate is separated out, filtering the solution, taking the precipitate, recrystallizing the precipitate by using ethanol, and drying in vacuum to obtain a target product, wherein the yield of the target product is 33.7-61.5%;
(3) mixing the target product prepared in the step (2) with one or more pharmaceutically acceptable carriers or excipients by using a conventional medicament, and preparing the mixture into a commercial pharmaceutical composition by using a preparation technology.
Further, the molar ratio of the methanol added in the step (1) to the laminine hydrochloride is 1-10: 1.
Further, the step (2) is added with 6-N, N, N-trimethyl-2-carbamyl methylamine hydrochloride and N- (5-bromo-2-hydroxyanilino) oxalyl ethyl ester in a molar ratio of 0.8-1.1: 1.
the laminine ester group bromo-oxamide derivative with anticancer activity and the composition thereof have the following beneficial effects:
1. the invention synthesizes a novel laminine ester group bromo-oxamide derivative with anticancer activity and a composition thereof by utilizing laminine which is a natural marine organism nonprotein, and expands the high-added-value application of natural marine resources;
2. the laminine ester bromo-oxamide derivative not only maintains the cationic property of laminine salt and has certain hydrophilicity, but also adjusts the three-dimensional structure and the hydrophilic-lipophilic balance value of molecules due to the introduction of a bromo-plane annular structure, and is more favorable for embedding protein molecules to attack cancer cell targets;
3. the implantation of the molecular structure of the ethanedione diamine is more beneficial to the interaction with the active center metal ions of the biological enzymes in the target protein molecules, so that the enzymes are inactivated, the apoptosis of cancer cells is promoted, and the accurate treatment effect is better.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments will be briefly introduced below.
FIG. 1 is an infrared spectrum (KBr pellet method) of the laminine-based bromooxamide derivative synthesized in example 1 of the present invention.
Detailed Description
The technical solution of the present invention will be described in detail with reference to the following embodiments:
example 1
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: refluxing 10mmol (2.24g) of laminarine hydrochloride in thionyl chloride for 2h, adding 50mmol (1.60g) of methanol, continuously refluxing for 8h, evaporating the redundant solvent, adjusting the pH value to be neutral by using dilute hydrochloric acid, separating out a white precipitate, filtering, washing with glacial ethanol and diethyl ether for multiple times respectively, and drying in vacuum to obtain a white solid 1.62g with the yield of 68.1%.
(2) Synthesis of laminine ester group bromo-oxamide derivative: 29mmol (8.19g) of ethyl N- (5-bromo-2-hydroxyanilino) oxaloacetate was dissolved in 30mL of absolute ethanol, slowly added dropwise to anhydrous THF containing 32mmol (7.58g) of 6-N, N, N-trimethyl-2-carbamoylmethylamine hydrochloride under ice bath conditions to maintain the reaction for 60min, heated to 85 ℃ for 6h, the solution was adjusted to neutral pH with dilute hydrochloric acid to precipitate a white precipitate, the solution was filtered, recrystallized from ethanol, and dried in vacuum to obtain the desired product 8.28g, yield 59.6%.
Referring to FIG. 1, FIG. 1 is an infrared spectrum (KBr pellet process) of the laminin-based bromooxamide derivative synthesized in example 1 of the present invention. As shown in fig. 1: the expansion vibration peaks of v (O-H) and v (N-H) of the target product appear at 3324cm-1Nearby; the peak of the stretching vibration of v (C-H) appears at a cm near 2973-1(ii) a The absorption of the stretching vibration of v (C ═ O) occurs at 1673cm-1Amide I band at 1585cm-1In the vicinity, the amide II band was 1501cm-1Nearby; the positive ion stretching vibration peak of quaternary ammonium salt is 2532cm-1And 1361cm-1And the functional groups of the laminine ester group bromo-oxamide derivative can be in one-to-one correspondence with the functional groups of the laminine ester group bromo-oxamide derivative.
Example 2
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: in the same manner as in example 1, the reflux time of only laminine hydrochloride in thionyl chloride was changed to 3 hours, and the reflux reaction time after addition of methanol was changed to 3 hours. The expected product was obtained in 1.04g with a yield of 43.7%.
(2) Synthesis of laminine ester group bromo-oxamide derivative: as in example 1, the molar ratio of ethyl N- (5-bromo-2-hydroxyanilino) oxaloacetate to 6-N, N, N-trimethyl-2-carbamoylmethylamine hydrochloride was changed to 1: 0.8, the reaction temperature was set to 35 ℃ and the reaction time was set to 10 hours, to obtain 4.68g of the target product, with a yield of 33.7%.
Example 3
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: in the same manner as in example 1, the reflux time of only laminine hydrochloride in thionyl chloride was changed to 2.4 hours, and the reflux reaction time after addition of methanol was changed to 8 hours. 1.36g of the expected product is obtained with a yield of 57.3%.
(2) Synthesis of laminine ester group bromo-oxamide derivative: as in example 1, the molar ratio of ethyl N- (5-bromo-2-hydroxyanilino) oxaloacetate to 6-N, N, N-trimethyl-2-carbamoylmethylamine hydrochloride alone was set to 1: 1. the reaction temperature was set at 85 ℃ and the reaction time was set at 4 hours. 7.17g of the target product was obtained in 51.6% yield.
Example 4
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: in the same manner as in example 1, the reflux time of only laminine hydrochloride in thionyl chloride was changed to 2.5 hours, and the reflux reaction time after addition of methanol was changed to 3 hours. The expected product was obtained in 1.15g with a yield of 48.3%.
(2) Synthesis of laminine ester group bromo-oxamide derivative: the same as in example 1.
Example 5
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: in the same manner as in example 1, the amount of methanol added was changed to 100mmol only to obtain 1.07g of the objective product in a yield of 45.1%.
(2) Synthesis of laminine ester group bromo-oxamide derivative: the same as in example 1.
Example 6
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: the same as in example 1.
(2) Synthesis of laminine ester group bromo-oxamide derivative: in the same manner as in example 1, only the dilute hydrochloric acid solution used for neutralization was changed to a dilute hydrobromic acid solution to obtain a bromide. 9.34g of the target product was obtained in a yield of 61.5%.
Example 7
(1) Synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: the same as in example 1.
(2) Synthesis of laminine ester group bromo-oxamide derivative: nitrate was obtained by changing only the dilute hydrochloric acid solution for neutralization to a dilute nitric acid solution in the same manner as in example 1. 7.82g of the target product is obtained with a yield of 53.3%.
In order to verify the anticancer activity of the laminine-based bromooxamide derivative, a known in vitro cytotoxic activity test was performed using cisplatin, a commercially available anticancer drug, as a control.
In vitro cytotoxicity assay Using SRB assay, the inhibition rate of the test sample against human hepatoma cell line (SMMC-7721), lung adenocarcinoma cell line (A549), human acute promyelocytic leukemia (HL-60) and normal mouse keratinocytes (Pam212) was calculated from the measured OD values by adding the compounds obtained in the above examples:
the half inhibitory concentration within 48h was determined by linear regression of the inhibition ratio with the concentration of the sample to be measured (IC 50). Cisplatin was used as a positive control. The results of IC50 obtained for representative compounds of the present invention for their anti-cancer activity are shown in the table.
As can be seen from the table, examples 1, 6 and 7 all had stronger inhibitory effects on the activity of cancer cells than cisplatin, an anticancer drug, and among them, the products of example 6 had the strongest inhibitory effects on SMMC-7721, A549 and HL-60.
Example 8
Preparation of tablets: 50g of the target product synthesized in example 1 was weighed, and the following ingredients were mixed by a conventional technique, granulated with 85% ethanol, dried, tabletted, and made into 1000 tablets, 2 tablets each time 3 times a day. The formula is as follows:
example 9
Preparation of sustained-release tablets: 100g of the target product synthesized in example 5 was weighed, and the following ingredients were mixed by a conventional technique, granulated with 90% ethanol, dried, tabletted, and made into 1000 tablets, 2 times a day, 1 tablet at a time.
The formula is as follows:
example 10
Preparation of capsules: 50g of the target product of the formula synthesized in example 6 was weighed, and by using a conventional technique, the following components were mixed, granulated with 85% ethanol, dried, and filled into hard capsules to prepare 1000 granules, 2 granules each time, 3 times a day.
The formula is as follows:
example 11
Preparation of lyophilized powder for injection: weighing 50g of the product in example 1 and 150g of mannitol, adding 2000mL of water for injection, stirring to dissolve, adjusting the pH to 6.60-7.00 with 1mol/L of NaOH solution, stirring to dissolve, filtering, adding activated carbon into the filtrate according to the volume amount of 1% of the solution, heating at 70-80 ℃ for 30min, roughly filtering, washing pipelines and containers with 400mL of water for injection, adding water to 2500mL, filtering the liquid medicine through a 0.22 mu m sterile filter, filling, freeze-drying, pressing a plug, rolling a cover, and preparing into 1000 bottles to obtain the oral liquid.
The above embodiments show that the target product prepared by the invention can effectively inhibit the growth of cancer cells, and the target product is mixed with one or more pharmaceutically acceptable carriers or excipients by conventional medicament and prepared into a commercial pharmaceutical composition by preparation technology.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (4)
1. An laminine-ester bromo-oxamide compound with anticancer activity, which is characterized in that the laminine-ester bromo-oxamide compound has a structural formula as follows:
the laminine ester bromo-oxamide compound has a structural formula in which the negative ion A is—Is Cl—Or Br—Or NO3 —。
2. The method for preparing the laminine-based bromo-oxamide compound having anticancer activity as claimed in claim 1, comprising the steps of:
(1) synthesis of methyl 6-N, N, N-trimethyl-2-carbamate hydrochloride: refluxing laminine hydrochloride in thionyl chloride for 2-3h, then adding methanol, continuously refluxing for 3-8h, evaporating redundant solvent, adjusting the pH value to be neutral by using dilute hydrochloric acid until white precipitate is separated out, filtering, washing with glacial ethanol and diethyl ether respectively for multiple times, and drying in vacuum to obtain a white solid product;
(2) synthesis of laminine ester bromo-oxamide compound: dissolving N- (5-bromo-2-hydroxyanilino) oxalyl ethyl ester in an absolute ethanol solution, slowly dropwise adding the anhydrous THF in which the 6-N, N, N-trimethyl-2-methyl carbamate hydrochloride prepared in the step (1) is dissolved under the ice bath condition, maintaining the reaction for 60min, then heating to 35-85 ℃, heating the reaction solution for 4-10h, adjusting the pH value of the solution to be neutral by using dilute hydrochloric acid or dilute hydrobromic acid solution until white precipitate is separated out, filtering the solution, taking the precipitate, recrystallizing the precipitate by using ethanol, and drying in vacuum to obtain the target product.
3. The method for preparing laminine-based bromo-oxamide compound having anticancer activity as claimed in claim 2, wherein the molar ratio of methanol to laminine hydrochloride added in step (1) is 1-10: 1.
4. the method for preparing the laminine-based bromo-oxamide compound having anticancer activity as claimed in claim 2, wherein the molar ratio of methyl 6-N, N-trimethyl-2-carbamate hydrochloride to ethyl N- (5-bromo-2-hydroxyanilino) oxamide compound added in the step (2) is 0.8-1.1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710818523.0A CN107540569B (en) | 2017-09-12 | 2017-09-12 | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710818523.0A CN107540569B (en) | 2017-09-12 | 2017-09-12 | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107540569A CN107540569A (en) | 2018-01-05 |
| CN107540569B true CN107540569B (en) | 2020-10-23 |
Family
ID=60963789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710818523.0A Active CN107540569B (en) | 2017-09-12 | 2017-09-12 | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107540569B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228276B (en) * | 2020-03-10 | 2023-05-23 | 王超 | Bromooxamide binuclear copper complex with antibacterial activity and composition thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103694133B (en) * | 2013-12-09 | 2016-05-25 | 青岛大学 | Synthetic and the pharmaceutical composition of laminine schiff bases with anticancer activity |
| CN103804399B (en) * | 2014-02-17 | 2016-10-05 | 青岛大学 | The synthesis of laminine schiff bases mononuclear complex with anticancer activity and pharmaceutical composition thereof |
-
2017
- 2017-09-12 CN CN201710818523.0A patent/CN107540569B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107540569A (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2914999C (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
| EP2535339A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
| JP5801873B2 (en) | Ester derivatives extracted from laughing flowers, drug combinations, preparation methods and uses | |
| EP2787002B1 (en) | Oleanolic acid amidate derivatives, preparation methods and uses thereof | |
| Dai et al. | Modulating the solubility and pharmacokinetic properties of 5-fluorouracil via cocrystallization | |
| CN101933930B (en) | Novel compound anti-coccidiosis medicament and preparation method thereof | |
| CN107540569B (en) | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof | |
| CN108084177B (en) | A kind of jamaicin 9- pyrazole derivatives and its preparation and application | |
| CN112209988A (en) | Tea sapogenin thiosemicarbazone zinc complex and preparation method and application thereof | |
| CN106317033B (en) | Silybin 23-substituted derivative and preparation method and application of injection thereof | |
| EP2994121A1 (en) | Treatment of cancer and other conditions using a transcription factor modulator | |
| CN107556211B (en) | Laminine ester oxamide with anticancer activity and synthesis method and application thereof | |
| CA2957290C (en) | Platinum (iv) complex with increased antitumor efficacy | |
| CN107602409B (en) | Laminarine bromide ester oxamide with anticancer activity and synthesis method and application thereof | |
| AU2016204180A1 (en) | Mogrosides and the salts thereof, the preparing method and the use of the same and pharmaceutical compositions comprising the mogrosides and the salts thereof | |
| Ji et al. | Catanionic drug-derivative nano-objects constructed by chlorambucil and its derivative for efficient leukaemia therapy | |
| CN102731396A (en) | Polyamine naphthalimide compounds and application of same in preparation of pharmaceutical preparation | |
| CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
| CN110642854A (en) | Polycrystalline form of fused ring compound, composition, preparation method and application thereof | |
| CN112279863A (en) | Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof | |
| CN113069554B (en) | Preparation method and application of oleanolic acid quaternary ammonium salt-heparin-chitosan nanoparticles | |
| CN113230246A (en) | Application of loganin aglycone in preparation of lung cancer prevention and treatment medicines | |
| CN105712994A (en) | Imidazolone-morphinan as well as preparation method and application thereof | |
| CN116947875A (en) | Mitochondrion-targeted rotenone-malonic acid-dequalinium chloride compound and preparation method and application thereof | |
| CN104356164B (en) | Compound as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 266000 Hongkong East Road, Laoshan District, Qingdao, Shandong Province, No. 7 Patentee after: QINGDAO University Address before: No.308 Ningxia road, Qingdao, Shandong 266000 Patentee before: QINGDAO University |